Mount Sinai Launches Incision-Free MRI-Guided Prostate Treatment with TULSA-PRO

Mount Sinai is reported as the first provider in metro New York to offer an incision-free, MRI-guided prostate treatment using TULSA-PRO. The announcement also notes that Profound commercializes Sonalleve, a therapeutic platform with several regulatory clearances.

Mount Sinai announced it is the first provider in metro New York to offer an incision-free, MRI-guided prostate treatment using TULSA-PRO. The announcement describes the procedure as guided by MRI and performed without an incision. The device maker Profound is identified in the release as commercializing other therapeutic platforms. The release included routine forward-looking language and risk disclosures. Key details: - Mount Sinai is reported as the first center in metro New York to deliver incision-free, MRI-guided prostate treatment with TULSA-PRO. - The treatment is described in the announcement as MRI-guided and incision-free; specific clinical outcomes were not detailed in the release. - The article notes Profound also commercializes Sonalleve, which is CE marked for multiple indications and has approvals including China NMPA clearance for uterine fibroids and an FDA Humanitarian Device Exemption for osteoid osteoma. - The press release contains forward-looking statements and mentions risks and uncertainties that could affect future results. Summary: The reported announcement establishes Mount Sinai as the first metro New York provider of TULSA-PRO for incision-free, MRI-guided prostate treatment. The device maker, Profound, is reported as marketing Sonalleve with several regulatory clearances and as exploring additional applications, and the release included forward-looking statements and risk disclaimers. Undetermined at this time.